Hormone and Metabolic Research最新文献

Asymmetric Dimethylarginine: A Never-Aging Story. 不对称二甲基精氨酸：永不衰老的故事。

IF 2 4区医学

Hormone and Metabolic Research Pub Date : 2025-05-26 DOI: 10.1055/a-2537-4692

Natalia Jarzebska, Stefan R Bornstein, Sergey Tselmin, Ulrich Julius, Barbara Cellini, Richard Siow, Mike Martin, Rajeshwar P Mookerjee, Arduino A Mangoni, Norbert Weiss, Roman Rodionov

{"title":"Asymmetric Dimethylarginine: A Never-Aging Story.","authors":"Natalia Jarzebska, Stefan R Bornstein, Sergey Tselmin, Ulrich Julius, Barbara Cellini, Richard Siow, Mike Martin, Rajeshwar P Mookerjee, Arduino A Mangoni, Norbert Weiss, Roman Rodionov","doi":"10.1055/a-2537-4692","DOIUrl":"https://doi.org/10.1055/a-2537-4692","url":null,"abstract":"Human aging is intrinsically associated with the onset and the progression of several disease states causing significant disability and poor quality of life. Although such association was traditionally considered immutable, recent advances have led to a better understanding of several critical biochemical pathways involved in the aging process. This, in turn, has stimulated a significant body of research to investigate whether reprogramming these pathways could delay the progression of human ageing and/or prevent relevant disease states, ultimately favoring healthier aging process. Cellular senescence is regarded as the principal causative factor implicated in biological and pathophysiological processes involved in aging. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase and an independent risk factor for several age-associated diseases. The selective extracorporeal removal of ADMA is emerging as a promising strategy to reduce the burden of age-associated disease states. This article discusses the current knowledge regarding the critical pathways involved in human aging and associated diseases and the possible role of ADMA as a target for therapies leading to healthier aging processes.","PeriodicalId":12999,"journal":{"name":"Hormone and Metabolic Research","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144150279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Outcomes of 68Ga-NODAGA-Exendin-4 PET/CT Guided Surgical Management of Insulinomas in MEN1: A Preliminary Study. 68Ga-NODAGA-Exendin-4 PET/CT引导下MEN1胰岛素瘤手术治疗的初步研究

IF 2 4区医学

Hormone and Metabolic Research Pub Date : 2025-05-23 DOI: 10.1055/a-2620-2931

Ketki Sunil Ambulkar, Ravikumar Shah, Anurag Lila, Anima Sharma, Rohit Barnabas, Manjiri Karlekar, Saba Samad Memon, Vijaya Sarathi, Priyanka Verma, Vikram Lele, Gaurav Malhotra, Sameer Rege, Tushar Bandgar

{"title":"Outcomes of 68Ga-NODAGA-Exendin-4 PET/CT Guided Surgical Management of Insulinomas in MEN1: A Preliminary Study.","authors":"Ketki Sunil Ambulkar, Ravikumar Shah, Anurag Lila, Anima Sharma, Rohit Barnabas, Manjiri Karlekar, Saba Samad Memon, Vijaya Sarathi, Priyanka Verma, Vikram Lele, Gaurav Malhotra, Sameer Rege, Tushar Bandgar","doi":"10.1055/a-2620-2931","DOIUrl":"https://doi.org/10.1055/a-2620-2931","url":null,"abstract":"The data on the use of 68Ga-NODAGA-exendin-4 PET/CT in localizing multiple endocrine neoplasia type 1 (MEN1)-related insulinomas is evolving; however, surgical outcomes data are not available. We describe our cohort of patients with MEN1-related endogenous hyperinsulinemic hypoglycemia (EHH), where 68Ga-NODAGA-exendin-4 PET/CT was used to guide conservative surgery. A retrospective record review of MEN1-related EHH cases managed between 2000 and 2024 was performed for clinical features, imaging, and management. Outcomes were assessed for patients whose surgical extent was determined by 68Ga-NODAGA-exendin-4 PET/CT versus conventional imaging (CECT and 68Ga-DOTATATE PET/CT). Five patients with a median age of 17 (15.5-18.5 years) with EHH underwent laparoscopic, single lesion enucleation based on 68Ga-NODAGA-exendin-4 PET/CT. On preoperative imaging, CT identified culprit lesion in four, while 68Ga-DOTATATE PET/CT localized in one, and had one false positive uptake in non-functioning NET. The median duration of hospital stay was 6 (5.5-9) days. Over a median follow-up of 48 (3.5-84.5) months, none had EHH recurrence or exocrine/endocrine pancreatic insufficiency. On follow-up, one patient had an uneventful pregnancy and delivery. In the remaining 15, who underwent surgery based on conventional imaging, 12 (80%) required extensive surgery beyond enucleation, of which two needed intraoperative ultrasound localization. This group had a postoperative hospital stay of 11 (8-23) days, one recurrence after 84 months, and pancreatic insufficiency in 5 (33%). Our center observation suggests that GLP1R-based PET/CT-guided conservative insulinoma surgery in MEN1 patients is effective and safe and needs further validation.","PeriodicalId":12999,"journal":{"name":"Hormone and Metabolic Research","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144132340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy, Safety, and Future of GLP-1 Receptor Agonists: A Systematic Literature Review and Meta-Analysis. GLP-1受体激动剂的疗效、安全性和未来：系统文献综述和荟萃分析。

IF 2 4区医学

Hormone and Metabolic Research Pub Date : 2025-05-23 DOI: 10.1055/a-2569-7315

Griffin Katz

{"title":"Efficacy, Safety, and Future of GLP-1 Receptor Agonists: A Systematic Literature Review and Meta-Analysis.","authors":"Griffin Katz","doi":"10.1055/a-2569-7315","DOIUrl":"https://doi.org/10.1055/a-2569-7315","url":null,"abstract":"GLP-1 receptor agonists have emerged as important therapeutic agents for type 2 diabetes mellitus (T2DM), but their comparative efficacy and broader applications remain subjects of ongoing research. The aim of the study was to evaluate and compare the efficacy, safety, and clinical applications of three GLP-1 receptor agonists - Semaglutide, Dulaglutide, and Exenatide - through systematic review and meta-analysis. A comprehensive search of PubMed/MEDLINE, Embase, Cochrane Library, Scopus, and Web of Science (2015-2023) identified 20 randomized controlled trials and observational studies. Primary outcomes included changes in HbA1c and body weight. Risk of bias was assessed using the Cochrane Collaboration's Risk of Bias tool. Semaglutide demonstrated superior efficacy with mean HbA1c reduction of 1.45% and weight loss of 1.44 kg. Dulaglutide showed consistent reductions in HbA1c (1.1%) and weight (1.2 kg). while Exenatide exhibited moderate effects. Meta-analysis revealed a significant pooled effect estimate favoring GLP-1 receptor agonists. with a mean HbA1c difference of -0.81 (95% CI: -0.92 to -0.70). Gastrointestinal side effects were most common, with Semaglutide showing the highest incidence. This meta-analysis establishes Semaglutide as the most effective GLP-1 receptor agonist for glycemic control and weight reduction, while Dulaglutide and Exenatide offer viable alternatives with fewer side effects. These findings support evidence-based decision-making in T2DM management and highlight the potential broader therapeutic applications of GLP-1 receptor agonists beyond diabetes care.","PeriodicalId":12999,"journal":{"name":"Hormone and Metabolic Research","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144132335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Expression profiles of glucocorticoid receptor α- and β-isoforms in diverse physiological and pathological conditions. 糖皮质激素受体α-和β-亚型在不同生理和病理条件下的表达谱。

IF 2 4区医学

Hormone and Metabolic Research Pub Date : 2025-05-22 DOI: 10.1055/a-2619-5035

Xiang Chen, Hongyu He

{"title":"Expression profiles of glucocorticoid receptor α- and β-isoforms in diverse physiological and pathological conditions.","authors":"Xiang Chen, Hongyu He","doi":"10.1055/a-2619-5035","DOIUrl":"https://doi.org/10.1055/a-2619-5035","url":null,"abstract":"Through alternative splicing, two isoforms of the glucocorticoid receptor (GR) gene are generated, termed GRα and GRβ. GRα is predominantly expressed and shows steroid binding activity, whereas GRβ is thought to be inactive as a result of its truncated ligand-binding domain. GRβ may only act as a dominant negative inhibitor when co-expressed with GRα. GRβ specifically binds RU486 and also exhibits intrinsic transcriptional activities to directly regulate the expression of a large number of genes via both GRα-dependent and GRα-independent mechanisms. Hypercortisolemia and hypocortisolemia show different effects on the expression profiles of GR isoforms. Inflammatory cytokines induce GRβ expression and lead to an increased GRβ/GRα ratio, which may be related to glucocorticoid resistance during inflammatory diseases. Because GRβ inhibits the activity of GRα, it has the potential to ameliorate glucocorticoid-induced abnormal metabolism, muscle loss or be used to treat tumors. While elevated GRβ expression has been found in some inflammatory diseases and may be relevant to glucocorticoid unresponsiveness, whether GRβ modulates glucocorticoid sensitivity in vivo is under debate because of its extremely low expression levels under physiological situations.","PeriodicalId":12999,"journal":{"name":"Hormone and Metabolic Research","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144127505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction: Testosterone Deprivation Impairs Cardiac Systolic Function in Orchiectomized Wistar Rats. 更正：睾酮剥夺损害去睾丸Wistar大鼠心脏收缩功能。

IF 2 4区医学

Hormone and Metabolic Research Pub Date : 2025-05-19 DOI: 10.1055/a-2597-9671

Gabriela Almeida Motta, Graziele Halmenschlager, Rachel Pinto Dornelles Dutra, Cláudia Ramos Rhoden, Ângela Maria Vicente Tavares, Alexandre Luz de Castro, Alex Sander da Rosa Araujo, Adriane Belló-Klein, Karen Breitenbach da Silva, Ernani Luis Rhoden

引用次数: 0

Testosterone Deprivation Impairs Cardiac Systolic Function in Orchiectomized Wistar Rats. 睾丸素剥夺损害去睾丸大鼠心脏收缩功能。

IF 2 4区医学

Hormone and Metabolic Research Pub Date : 2025-04-22 DOI: 10.1055/a-2569-7387

Gabriela Almeida Motta, Graziele Halmenschlager, Rachel Pinto Dornelles Dutra, Cláudia Ramos Rhoden, Ângela Maria Vicente Tavares, Alexandre Luz de Castro, Alex Sander da Rosa Araujo, Adriane Belló-Klein, Karen Breitenbach da Silva, Ernani Luis Rhoden

{"title":"Testosterone Deprivation Impairs Cardiac Systolic Function in Orchiectomized Wistar Rats.","authors":"Gabriela Almeida Motta, Graziele Halmenschlager, Rachel Pinto Dornelles Dutra, Cláudia Ramos Rhoden, Ângela Maria Vicente Tavares, Alexandre Luz de Castro, Alex Sander da Rosa Araujo, Adriane Belló-Klein, Karen Breitenbach da Silva, Ernani Luis Rhoden","doi":"10.1055/a-2569-7387","DOIUrl":"10.1055/a-2569-7387","url":null,"abstract":"Several studies have linked low levels of testosterone with increased symptoms of cardiac disease and cardiovascular mortality; however, the effects of testosterone deficiency on cardiac systolic function and morphology are still not completely elucidated. The present study aims to evaluate the influence of testosterone deprivation on cardiac systolic function and morphology. Male Wistar rats were divided into two groups: Sham operation group (Sham): animals underwent sham operation and Orchiectomized group (Orchiec): animals underwent bilateral orchiectomy. The experimental protocol lasted 60 days after the surgery. All animals were weighted and blood samples collected to serum testosterone analysis, determined by chemiluminescence, on first (before orchiectomy) and on 60th days. One day before euthanasia (on the 59th day) echocardiographic parameters were assessed to evaluate left ventricle (LV) systolic function and morphology. Statistical significant difference was set at≤0.05. Orchiec rats presented reduced LV fractional shortening (p=0.032), increased myocardial performance index (MPI) (p=0.043), prolonged mitral valve closure time (p=0.013) and decreased heart rate (p=0.049) when compared to Sham. No statistically significant difference was found in the ejection fraction (p=0.666) between groups. Besides that, heart weight was lower in Orchiec group (p=0.035) when compared to Sham group. Testosterone deprivation reduced cardiac systolic function, changing contraction and relaxation parameters. Testosterone deficiency also changed heart rate and heart weight. The present study demonstrated for the first time that castrated levels of testosterone could alter parameters such as mitral valve closing time and MPI.","PeriodicalId":12999,"journal":{"name":"Hormone and Metabolic Research","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Proteomic Profiling of Age-Related Proteins Following Extracorporeal Apheresis. 体外分离后年龄相关蛋白的蛋白质组学分析。

IF 2 4区医学

Hormone and Metabolic Research Pub Date : 2025-04-15 DOI: 10.1055/a-2563-1187

Romy Walther, Bhawana Singh, Xiaoke Yin, Philip Mavberg, Anna Mücke, Roman Rodionov, Mahmoud Babir, Manuel Mayr, Stefan R Bornstein

{"title":"Proteomic Profiling of Age-Related Proteins Following Extracorporeal Apheresis.","authors":"Romy Walther, Bhawana Singh, Xiaoke Yin, Philip Mavberg, Anna Mücke, Roman Rodionov, Mahmoud Babir, Manuel Mayr, Stefan R Bornstein","doi":"10.1055/a-2563-1187","DOIUrl":"https://doi.org/10.1055/a-2563-1187","url":null,"abstract":"Lipoprotein apheresis (LA) is often the last option to adequately reduce lipoproteins in patients with familial hypercholesterolemia and lipoprotein (a) hyperlipidemia. Characterized by mild side effects, it is now the most effective method of preventing major cardiovascular events (CVEs). This benefit is due not only to the lowering of lipoprotein levels, but probably also to many other pleiotropic effects that have been extensively described in the literature. These include the reduction of inflammatory signaling substances, fibrinogen, plasminogen or components of the oxidative stress response. Here, we performed a proteomic analysis of 12 patients treated with therapeutic apheresis using two different pore size filters to quantify the effect on age-related plasma proteins. This study showed that important proteins such as α-2-macroglobulin, apolipoprotein C-III, complement C1s subcomponent, C4b-binding protein alpha chain, CD5 antigen-like and pregnancy zone protein, whose role in numerous aging processes has been well described, were significantly reduced by apheresis treatment. We conclude that therapeutic apheresis may be a promising approach to reduce these age-related proteins and that these treatments may become an essential part of managing cardiovascular risk in an aging population.","PeriodicalId":12999,"journal":{"name":"Hormone and Metabolic Research","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144003130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can Lipoprotein(a) Predict the Risk of Diabetic Nephropathy in Type 2 Diabetes Mellitus?: A Systematic Review and Meta-Analysis. 脂蛋白(a)能否预测2型糖尿病肾病的风险？：系统回顾与元分析。

IF 2 4区医学

Hormone and Metabolic Research Pub Date : 2025-04-01 Epub Date: 2025-04-10 DOI: 10.1055/a-2554-0696

Feixiang Wu, Chenmin Cui, Junping Wu, Yunqing Wang

{"title":"Can Lipoprotein(a) Predict the Risk of Diabetic Nephropathy in Type 2 Diabetes Mellitus?: A Systematic Review and Meta-Analysis.","authors":"Feixiang Wu, Chenmin Cui, Junping Wu, Yunqing Wang","doi":"10.1055/a-2554-0696","DOIUrl":"https://doi.org/10.1055/a-2554-0696","url":null,"abstract":"We aimed to examine if serum lipoprotein(a) [Lp(a)] values could be used to predict the risk of diabetic nephropathy (DN) in type 2 diabetes mellitus (T2DM). English-language observational studies available as full-texts on PubMed, Embase, Scopus, and Web of Science databases up to 28th November 2024 were included in the review. Studies were to assess the association between Lp(a) and DN and report adjusted effect size. Random-effects meta-analysis was conducted. Five cross-sectional, two case-control, and eight studies prospective cohort were included. Six studies used Lp(a) as a continuous variable while eight used it as a categorical variable. Two studies used Lp(a) as both. Meta-analysis showed that an incremental increase in Lp(a) was associated with a small increase in the risk of DN (OR: 1.03 95% CI: 1.01, 1.04 I2=86%). Meta-analysis also showed that high levels of Lp(a) were associated with a significant increase in the risk of DN (OR: 1.64 95% CI: 1.24, 2.17 I2=67%). Subgroup analysis based on study design, location, sample size, T2DM duration, baseline HbA1c, and definition of DN yielded mixed results. Lp(a) could be a potential marker for DN in T2DM. Further investigations may provide better evidence.","PeriodicalId":12999,"journal":{"name":"Hormone and Metabolic Research","volume":"57 4","pages":"242-251"},"PeriodicalIF":2.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic Assessment and Analysis of Underlying Biological Mechanisms of Prostate Cancer Based on Estrogen-Related Genes. 基于雌激素相关基因的前列腺癌预后评估及潜在生物学机制分析。

IF 2 4区医学

Hormone and Metabolic Research Pub Date : 2025-04-01 Epub Date: 2025-04-10 DOI: 10.1055/a-2548-1568

Heng Zhang, Meng-Die Fan, Yang Hu, Qing Yang, Jia-Wei Jiang, Min Xu

{"title":"Prognostic Assessment and Analysis of Underlying Biological Mechanisms of Prostate Cancer Based on Estrogen-Related Genes.","authors":"Heng Zhang, Meng-Die Fan, Yang Hu, Qing Yang, Jia-Wei Jiang, Min Xu","doi":"10.1055/a-2548-1568","DOIUrl":"https://doi.org/10.1055/a-2548-1568","url":null,"abstract":"Prostate cancer (PCa) ranks among the most prevalent cancers in men, noted for its high mortality rate and unfavorable prognosis. Estrogen-related genes (ERGs) are significantly associated with the progression of PCa. This investigation aims to comprehensively assess the prognosis of PCa based on ERGs and explore its underlying biological mechanisms. Univariate, multivariate, and Least Absolute Shrinkage and Selection Operator (LASSO) regression analyses were conducted to identify prognostic signature genes and build a prognostic model. The model's predictive performance was assessed using Receiver Operating Characteristic (ROC) curve analysis. Gene Set Enrichment Analysis (GSEA), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were employed to investigate the underlying molecular mechanisms of PCa. Antitumor drugs with high sensitivity were predicted using the CellMiner database and the pRRophitic package. Additionally, miRNAs targeting the identified signature genes were predicted using the miRNet database. This study identified six ERGs as prognostic biomarkers for PCa: POU4F1, BMP2, PGF, GAS1, GNAZ, and FGF11. The findings indicated that individuals in the low-risk category exhibited improved prognostic results. Notably, PCa progression may be closely linked to the cell adhesion molecule pathway and epigenetic regulation. Additionally, hsa-let-7a-5p and hsa-miR-34a-5p were identified as potential therapeutic regulators for PCa treatment. In conclusion, this research offers novel perspectives into the progression of PCa, providing robust scientific support for the development of personalized treatment strategies for PCa patients.","PeriodicalId":12999,"journal":{"name":"Hormone and Metabolic Research","volume":"57 4","pages":"273-285"},"PeriodicalIF":2.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Time Adjustment of Hydrocortisone Doses During Shift Work in Patients with Adrenal Insufficiency. 肾上腺功能不全患者轮班工作时氢化可的松剂量的时间调整。

IF 2 4区医学

Hormone and Metabolic Research Pub Date : 2025-04-01 Epub Date: 2025-03-02 DOI: 10.1055/a-2549-5784

Tina Kienitz, Christian Strasburger, Ulf Elbelt, Katharina Lang, Knut Mai, Thomas Bobbert, Marcus Quinkler

{"title":"Time Adjustment of Hydrocortisone Doses During Shift Work in Patients with Adrenal Insufficiency.","authors":"Tina Kienitz, Christian Strasburger, Ulf Elbelt, Katharina Lang, Knut Mai, Thomas Bobbert, Marcus Quinkler","doi":"10.1055/a-2549-5784","DOIUrl":"10.1055/a-2549-5784","url":null,"abstract":"Shift work causes a disruption between the circadian system and the external light-dark cycle, but also a misalignment between various levels of the circadian system. There is no information on patients with adrenal insufficiency (AI) who are working shifts. The objective of the study was to analyze the hormone replacement therapy with hydrocortisone (HC) and the adaptation scheme in patients with AI on shifts. Patients working on shifts (n=15) from two German endocrine centers received a questionnaire regarding their therapy scheme, dose adaptations, working shifts, dose adaptations during working shifts, and occurrence of adrenal crisis. We observed that 20% of patients stated that they experience difficulties taking glucocorticoid replacement on time, 40% of patients reported these difficulties to occur only occasionally. Consequently, nearly half of the patients had forgotten to take their replacement therapy at some point. More than 50% of patients reported an adrenal crisis during the last two years. The timely adaptation of HC or of modified-release HC during shifts was very inhomogeneous. In conclusion, the adaptation schemes for HC dosing during shift work are currently not evidence-based but opinion-driven. Our findings highlight the need for further investigations of shift workers with AI.","PeriodicalId":12999,"journal":{"name":"Hormone and Metabolic Research","volume":" ","pages":"236-241"},"PeriodicalIF":2.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143536952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0